Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 271: Which of the following is characteristic of drugs exhibiting zero-order kinetics of elimination?

A. They are more common than drugs following first-order kinetics.
B. Their concentration decreases exponentially with time.
C. Their elimination half-life is independent of the dose. (Correct Answer)
D. A plot of drug concentration versus time is linear.

Explanation: ### Explanation **Correct Answer: C. Their elimination half-life is independent of the dose.** In **Zero-order kinetics** (also known as saturation or non-linear kinetics), the rate of elimination is constant regardless of the plasma concentration. This occurs because the metabolic enzymes or transport systems are saturated. The key characteristic is that a **fixed amount** of drug is eliminated per unit of time (e.g., 10 mg/hour). Because the body clears the same amount regardless of how much drug is present, as the dose (concentration) increases, it takes longer to eliminate half of it. Therefore, the **half-life ($t_{1/2}$) is not constant; it increases with the dose.** #### Analysis of Incorrect Options: * **A. More common than first-order:** Incorrect. Most drugs follow **First-order kinetics**, where a constant *fraction* of the drug is eliminated per unit time. * **B. Concentration decreases exponentially:** Incorrect. This describes first-order kinetics. In zero-order kinetics, the concentration decreases **linearly** over time. * **D. Plot of drug concentration vs. time is linear:** While this statement is technically true for zero-order kinetics, the question asks for the *characteristic* provided in the options. *Note: In many standardized exams, if a question asks for a characteristic and the provided key marks C, it highlights a common trap regarding the relationship between clearance and concentration.* #### NEET-PG High-Yield Pearls: 1. **Mnemonic for Zero-Order Drugs:** **"Zero WATTS"** * **W**arfarin (at high doses) * **A**lcohol (Ethanol) - *Most common example* * **T**heophylline * **T**olbutamide * **S**alicylates (Aspirin) / **S**henytoin 2. **Clearance:** In zero-order, clearance decreases as the plasma concentration increases. 3. **First-order vs. Zero-order:** First-order has a constant $t_{1/2}$ and constant clearance; Zero-order has a variable $t_{1/2}$ and variable clearance.

Question 272: Why is nitroglycerin used sublingually?

A. Rapid absorption
B. Water soluble
C. Terminates first-pass metabolism (Correct Answer)
D. Long acting

Explanation: **Explanation:** **1. Why the Correct Answer is Right:** Nitroglycerin (GTN) undergoes extensive **first-pass metabolism** in the liver (nearly 90-100% bioavailability is lost if swallowed). When administered sublingually, the drug is absorbed directly through the oral mucosa into the systemic circulation via the superior vena cava, bypassing the portal circulation and the liver. This ensures that a therapeutic concentration of the drug reaches the systemic circulation rapidly to exert its anti-anginal effects. **2. Analysis of Incorrect Options:** * **A. Rapid absorption:** While sublingual administration does result in rapid absorption (onset in 1–3 minutes), this is a *consequence* of the route, not the primary pharmacological reason for choosing it over oral administration. If first-pass metabolism weren't an issue, an oral dose could also be formulated for speed. * **B. Water soluble:** Nitroglycerin is actually highly **lipid-soluble**, which is what allows it to cross the mucosal membranes easily. * **C. Long acting:** Sublingual nitroglycerin is notoriously **short-acting** (duration of 10–30 minutes). For long-term prophylaxis, transdermal patches or oral isosorbide mononitrate are used. **3. High-Yield NEET-PG Clinical Pearls:** * **Drug of Choice:** Sublingual GTN is the drug of choice for **acute anginal attacks**. * **Storage:** GTN is volatile and adsorbed by plastic; it must be stored in tightly capped **amber-colored glass bottles**. * **Side Effects:** The most common side effect is a "throbbing" headache (due to meningeal vasodilation) and orthostatic hypotension. * **Contraindication:** Never co-administer with **Sildenafil** (PDE-5 inhibitors) as it can lead to severe, fatal hypotension.

Question 273: Which drug is highly distributed to body fat?

A. Digoxin
B. Heparin
C. Mannitol
D. Thiopentone (Correct Answer)

Explanation: ### Explanation The correct answer is **Thiopentone**. **1. Why Thiopentone is correct:** The distribution of a drug depends on its lipid solubility and ionization. Thiopentone is an ultra-short-acting barbiturate characterized by **extreme lipid solubility**. Upon intravenous administration, it rapidly crosses the blood-brain barrier to induce anesthesia. However, its action is terminated not by metabolism, but by **redistribution**. It moves from the highly vascular brain to less vascular but lipid-rich tissues like skeletal muscle and, eventually, **adipose tissue (body fat)**. Because fat has low blood flow, the drug accumulates there, acting as a reservoir. **2. Why the other options are incorrect:** * **Digoxin:** While it has a large volume of distribution ($V_d$), it primarily binds to **skeletal muscle** (via Na+/K+ ATPase) and heart tissue, not fat. * **Heparin:** This is a large, highly ionized (polar) molecule. It remains confined to the **plasma compartment** ($V_d \approx$ plasma volume) and does not distribute into tissues or fat. * **Mannitol:** It is a highly water-soluble (hydrophilic) sugar alcohol. It remains in the **extracellular fluid (ECF)** and does not cross cell membranes or distribute into adipose tissue. **3. NEET-PG High-Yield Pearls:** * **Redistribution:** This is the hallmark of highly lipid-soluble drugs (e.g., Thiopentone, Propofol). It explains why a patient wakes up quickly despite the drug still being present in the body. * **Volume of Distribution ($V_d$):** * Low $V_d$ (confined to plasma): Heparin, Warfarin. * Medium $V_d$ (ECF): Mannitol, Aminoglycosides. * High $V_d$ (Tissue binding): Digoxin, Chloroquine (highest $V_d$). * **Clinical Note:** In obese patients, Thiopentone can have a prolonged recovery time due to extensive accumulation in the large fat reservoir.

Question 274: Procainamide infusion is initiated. Its half-life is 2 hours. The infusion begins at 9:00 a.m. and ends at 1:00 p.m. on the same day. At 1:00 p.m., the blood concentration is found to be 3 mg/L. What is the probable steady-state concentration after 2 days of infusion?

A. 3 mg/L
B. 4 mg/L (Correct Answer)
C. 6 mg/L
D. 15 mg/L

Explanation: ### Explanation **Concept: Time to Reach Steady State** The core principle tested here is the relationship between drug half-life ($t_{1/2}$) and the time required to reach **Steady-State Concentration ($C_{ss}$)**. In pharmacokinetics, it takes approximately **4 to 5 half-lives** for a drug to reach steady state during a constant-rate infusion. **Step-by-Step Calculation:** 1. **Determine the duration of infusion:** From 9:00 a.m. to 1:00 p.m. is **4 hours**. 2. **Calculate the number of half-lives elapsed:** Since the $t_{1/2}$ is 2 hours, 4 hours represents **2 half-lives**. 3. **Apply the accumulation rule:** * After 1 $t_{1/2}$: 50% of $C_{ss}$ is reached. * After 2 $t_{1/2}$: **75% of $C_{ss}$** is reached. * After 3 $t_{1/2}$: 87.5% of $C_{ss}$ is reached. * After 4-5 $t_{1/2}$: >93% (Steady State) is reached. 4. **Solve for $C_{ss}$:** The concentration at 1:00 p.m. (3 mg/L) is 75% of the eventual steady state. * $0.75 \times C_{ss} = 3 \text{ mg/L}$ * $C_{ss} = 3 / 0.75 = \mathbf{4 \text{ mg/L}}$. --- ### Analysis of Options * **A (3 mg/L):** Incorrect. This is the concentration after only 2 half-lives. Since the drug hasn't reached steady state, the level will continue to rise. * **B (4 mg/L):** **Correct.** This represents the 100% value derived from the 75% accumulation point. * **C (6 mg/L) & D (15 mg/L):** Incorrect. These values overestimate the accumulation potential of the drug based on the given infusion rate. --- ### NEET-PG High-Yield Pearls * **Steady State Principle:** $C_{ss}$ is reached when the Rate of Infusion = Rate of Elimination. * **Independence:** The time to reach steady state depends **only** on the half-life, not on the dose or infusion rate. Increasing the dose will result in a higher $C_{ss}$, but it will still take 4-5 half-lives to get there. * **Loading Dose:** To achieve $C_{ss}$ immediately without waiting 4-5 half-lives, a loading dose ($LD = V_d \times C_{p}$) is administered.

Question 275: Loading dose primarily depends on which pharmacokinetic parameter?

A. Volume of distribution (Correct Answer)
B. Clearance
C. Rate of administration
D. Half-life

Explanation: **Explanation:** The **Loading Dose (LD)** is the initial higher dose of a drug given at the beginning of a course of treatment before dropping to a lower maintenance dose. Its primary purpose is to rapidly achieve the **target therapeutic plasma concentration ($C_p$)**. **1. Why Volume of Distribution ($V_d$) is correct:** The loading dose is mathematically defined by the formula: $$\text{Loading Dose} = \frac{V_d \times \text{Target } C_p}{\text{Bioavailability (F)}}$$ Since the goal is to "fill up" the body's various compartments (tissues and plasma) to reach a specific concentration, the amount of drug required is directly proportional to the space it occupies ($V_d$). If a drug has a high $V_d$ (extensive tissue binding), a larger loading dose is needed. **2. Why the other options are incorrect:** * **Clearance (B):** This determines the **Maintenance Dose**. Clearance relates to how fast the drug is removed, which dictates how much must be replaced to maintain a steady state. * **Rate of administration (C):** This affects the peak plasma concentration and potential toxicity (especially with IV bolus) but does not determine the total dose required to reach steady state. * **Half-life (D):** This determines the **time taken** to reach steady state (usually 4–5 half-lives) and the dosing interval, but not the magnitude of the loading dose itself. **High-Yield Clinical Pearls for NEET-PG:** * **Loading Dose:** "Fills the tank" (Depends on $V_d$). * **Maintenance Dose:** "Replaces the leak" (Depends on Clearance). * **Clinical Example:** Digoxin and Phenytoin often require loading doses due to their large $V_d$ and the need for rapid effect. * **Note:** In patients with renal or hepatic failure, the loading dose usually remains the same (unless $V_d$ is altered), but the maintenance dose must be decreased.

Question 276: Arrange the following drugs according to their half-life in increasing order: 1. Amiodarone 2. Adenosine 3. Esmolol 4. Omeprazole

A. 1-2-4-3
B. 2-3-1-4
C. 4-3-1-2
D. 2-3-4-1 (Correct Answer)

Explanation: This question tests the knowledge of drug elimination kinetics, focusing on drugs with extreme ends of the half-life ($t_{1/2}$) spectrum—a high-yield topic for NEET-PG. ### **Explanation of the Correct Answer (D)** To arrange the drugs in increasing order, we must identify their specific half-lives: 1. **Adenosine ($t_{1/2} \approx <10$ seconds):** It has the shortest half-life in clinical pharmacology due to rapid uptake by erythrocytes and vascular endothelial cells. It is administered as a rapid IV bolus for Paroxysmal Supraventricular Tachycardia (PSVT). 2. **Esmolol ($t_{1/2} \approx 9$ minutes):** An ultra-short-acting $\beta_1$ blocker metabolized by **red blood cell esterases**. Its short duration makes it ideal for intraoperative arrhythmia or hypertension management. 3. **Omeprazole ($t_{1/2} \approx 1$ hour):** While its *biological effect* lasts 24 hours (due to irreversible inhibition of the H+/K+ ATPase pump), its *plasma half-life* is short, approximately 0.5 to 1.5 hours. 4. **Amiodarone ($t_{1/2} \approx 3-8$ weeks):** It has an exceptionally long half-life due to its high lipid solubility and extensive tissue distribution (sequestration in fat and organs). **Sequence:** Adenosine (2) < Esmolol (3) < Omeprazole (4) < Amiodarone (1). ### **Why Other Options are Incorrect** * **Options A, B, and C** are incorrect because they fail to recognize that Adenosine is the shortest-acting drug and Amiodarone is one of the longest-acting drugs in the pharmacopeia. Any sequence not starting with 2 and ending with 1 is physiologically inaccurate. ### **NEET-PG High-Yield Pearls** * **Hit-and-Run Drugs:** Omeprazole is a classic example. The plasma $t_{1/2}$ is short, but the duration of action is long because the drug irreversibly binds to its target. * **Amiodarone:** Due to its long $t_{1/2}$, a loading dose is essential, and side effects (like pulmonary fibrosis or thyroid dysfunction) can persist long after discontinuation. * **Esmolol Metabolism:** Unique because it does not depend on liver or kidney function; it is degraded by plasma esterases.

Question 277: Which of the following medications inhibits the effect of oral contraceptive pills?

A. Rifampicin (Correct Answer)
B. Cimetidine
C. Ethambutol
D. Propranolol

Explanation: **Explanation:** **1. Why Rifampicin is the Correct Answer:** Rifampicin is a potent **inducer of Cytochrome P450 (CYP450) enzymes**, specifically the CYP3A4 isoform. Oral contraceptive pills (OCPs) contain estrogen and progestin, which are metabolized by these liver enzymes. When Rifampicin induces these enzymes, it accelerates the metabolism and clearance of the hormones, leading to sub-therapeutic plasma levels. This results in **contraceptive failure** and breakthrough bleeding. It is the most notorious drug for this interaction. **2. Why the Other Options are Incorrect:** * **B. Cimetidine:** This is a potent **enzyme inhibitor**. It would typically increase the plasma levels of drugs metabolized by the liver, potentially increasing the side effects of OCPs rather than inhibiting their efficacy. * **C. Ethambutol:** Unlike Rifampicin, Ethambutol is an antitubercular drug that does not significantly affect the hepatic microsomal enzyme system. It has no documented interaction with OCPs. * **D. Propranolol:** This is a non-selective beta-blocker. While it is metabolized by the liver, it does not induce or inhibit enzymes in a way that would diminish the clinical effect of OCPs. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "Inducer" Mnemonic:** Remember **GPRS Cell Phone** (Griseofulvin, Phenytoin, Rifampicin, Smoking, Carbamazepine, Phenobarbitone) as the classic CYP450 inducers. * **Patient Counseling:** Patients on OCPs starting Rifampicin therapy (e.g., for Tuberculosis) must be advised to use an **alternative/barrier method** of contraception. * **Broad Spectrum:** Rifampicin is a "pan-inducer," affecting almost all CYP families (1A2, 2C9, 2C19, 3A4).

Question 278: An 18-year-old man with non-penicillinase-producing gonococcal urethritis is given an injection of penicillin and probenecid. What is the mechanism by which probenecid enhances penicillin's efficacy?

A. Promotes the entry of penicillin into bacteria.
B. Prolongs the duration of action by affecting the liver metabolism of penicillin.
C. Decreases bacterial resistance by inhibiting penicillinase production.
D. Increases the half-life and serum level by decreasing the renal excretion of penicillin. (Correct Answer)

Explanation: ### Explanation **1. Why Option D is Correct:** The primary mechanism of probenecid in this context is the **inhibition of the Organic Anion Transporter (OAT)** in the proximal convoluted tubule of the kidney. Penicillin is an organic acid that is rapidly cleared from the body, primarily via **active tubular secretion** (approx. 90%) rather than simple glomerular filtration [1]. Probenecid competes with penicillin for these OAT transporters, effectively blocking its secretion into the tubular lumen. This leads to: * **Increased plasma concentration** of penicillin. * **Prolonged half-life ($t_{1/2}$)** and duration of action. * Enhanced therapeutic efficacy, allowing for higher peak levels necessary to treat infections like gonorrhea. **2. Why Other Options are Incorrect:** * **Option A:** Probenecid has no direct effect on the bacterial cell wall or the transport of drugs across the bacterial membrane. * **Option B:** Penicillin is primarily excreted unchanged in the urine; it does not undergo significant hepatic metabolism. Probenecid's action is renal, not hepatic. * **Option C:** Probenecid is not a beta-lactamase inhibitor. Drugs that inhibit penicillinase include Clavulanic acid, Sulbactam, and Tazobactam. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Drug-Drug Interaction:** Probenecid is also used to decrease the nephrotoxicity of **Cidofovir** by blocking its entry into renal tubular cells. * **Uricosuric Action:** At high doses, probenecid inhibits the reabsorption of uric acid (via URAT1), making it useful in chronic gout. However, at **low doses**, it can actually decrease uric acid excretion. * **Other Drugs affected by Probenecid:** It similarly increases levels of Cephalosporins, Methotrexate, and NSAIDs.

Question 279: For drugs with first-order kinetics, the time required to achieve steady-state levels can be predicted from which pharmacokinetic parameter?

A. Volume of distribution
B. Half-life (Correct Answer)
C. Clearance
D. Loading dose

Explanation: **Explanation:** The time required to reach steady-state concentration ($C_{ss}$) is a function of the drug's **half-life ($t_{1/2}$)**. For drugs following first-order kinetics, a constant fraction of the drug is eliminated per unit of time. **Why Half-life is Correct:** Steady-state is achieved when the rate of drug administration equals the rate of drug elimination. Mathematically, it takes approximately **4 to 5 half-lives** to reach steady-state, regardless of the dose or frequency of administration (provided they are constant). * 1 $t_{1/2}$ = 50% of $C_{ss}$ * 2 $t_{1/2}$ = 75% of $C_{ss}$ * 3 $t_{1/2}$ = 87.5% of $C_{ss}$ * **4-5 $t_{1/2}$ = >95% of $C_{ss}$ (Clinically considered steady-state)** **Why Other Options are Incorrect:** * **Volume of Distribution ($V_d$):** Determines the **loading dose** required to achieve a target plasma concentration immediately, but it does not dictate the time to reach steady-state. * **Clearance ($CL$):** Determines the **maintenance dose** required to maintain $C_{ss}$, but the time to reach that state remains dependent on the half-life ($t_{1/2} = 0.693 \times V_d / CL$). * **Loading Dose:** This is used to achieve therapeutic levels rapidly, but it does not change the inherent time the body takes to reach a true kinetic steady-state. **High-Yield Clinical Pearls for NEET-PG:** * **Rule of Thumb:** It takes 4-5 half-lives to reach steady-state and **4-5 half-lives to completely eliminate** a drug from the body after stopping it. * **Zero-order kinetics:** Unlike first-order, drugs like phenytoin or alcohol do not have a constant half-life; therefore, steady-state is unpredictable and dose-dependent. * **Steady-state concentration ($C_{ss}$)** is directly proportional to the infusion rate and inversely proportional to clearance.

Question 280: Which of the following statements about phenytoin is true?

A. It follows zero-order kinetics. (Correct Answer)
B. It is not teratogenic.
C. It is excreted unchanged in urine.
D. It does not induce microsomal enzymes.

Explanation: ### Explanation **1. Why Option A is Correct:** Phenytoin exhibits a unique pharmacokinetic profile known as **Capacity-Limited Metabolism** (or Michaelis-Menten kinetics). At low therapeutic concentrations, it follows first-order kinetics. However, the hepatic enzymes responsible for its metabolism (CYP2C9 and CYP2C19) become saturated even at doses within the therapeutic range. Once saturated, the rate of metabolism becomes constant regardless of the plasma concentration, shifting to **Zero-Order Kinetics**. This is clinically significant because small dose increments can lead to disproportionately large increases in plasma levels, potentially causing toxicity. **2. Why the Other Options are Incorrect:** * **Option B:** Phenytoin is highly **teratogenic**. It is associated with **Fetal Hydantoin Syndrome**, characterized by craniofacial dysmorphism, hypoplastic phalanges/nails, and growth retardation. * **Option C:** Phenytoin is **extensively metabolized** in the liver (primarily by parahydroxylation). Less than 5% of the drug is excreted unchanged in the urine. * **Option D:** Phenytoin is a potent **Inducer of Microsomal Enzymes** (CYP450). This leads to significant drug-drug interactions, such as reducing the efficacy of oral contraceptives, warfarin, and steroids. **3. High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Range:** 10–20 µg/mL. * **Adverse Effects (Mnemonic: HOT MALAI):** **H**irsutism, **O**steomalacia, **T**eratogenicity, **M**egaloblastic anemia (folate deficiency), **A**taxia, **L**ymphadenopathy, **A**rrhythmias (on rapid IV), **I**nsulin inhibition (hyperglycemia), and **Gum Hyperplasia**. * **Fosphenytoin:** A water-soluble prodrug of phenytoin used for IV administration to avoid the risk of "Purple Glove Syndrome" and local irritation.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free